Compass Therapeutics, Inc. $CMPX

By Microcap Ledger desk · CIK 0001738021

Facts as of Oct 11, 2026, 08:07 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Biological Products, (No Diagnostic Substances)
Headquarters: Boston, MA
Fiscal year end: December 31
Shares outstanding: 180,087,915 [10-Q 2026-08-06]
as of 2026-07-28

Sources: [10-K 2026-03-05]

What the company doesAI summary of filing

Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for oncology. The company has four clinical-stage product candidates: tovecimig (a DLL4/VEGF-A bispecific antibody in Phase 2/3 trials for biliary tract cancer), CTX-471 (a CD137 agonist antibody in Phase 1b trials), CTX-8371 (a PD-1/PD-L1 bispecific antibody in Phase 1 trials), and CTX-10726 (a PD-1/VEGF-A bispecific antibody in early Phase 1 development). The company has not generated revenue from product sales and expects to continue incurring significant losses for the foreseeable future. [10-K 2026-03-05]

Segments: Tovecimig (CTX-009), CTX-471, CTX-8371, CTX-10726

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$43.47M	−$32.01M	$35.45M	[10-Q 2026-08-06]
FY ended Dec 2025	$0.00	−$66.49M	−$49.14M	$30.64M	[10-K 2026-03-05]
FY ended Dec 2024	$850.0K	−$49.38M	−$44.85M	$43.48M	[10-K 2026-03-05]

Quarterly cash burn: −$16.00M
Cash runway Estimate: ~6.6 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-08	137,589,171	[10-Q 2024-11-12]
2025-02-15	138,282,498	[10-K 2025-02-27]
2025-04-28	138,282,498	[10-Q 2025-05-08]
2025-08-04	138,282,498	[10-Q 2025-08-11]
2025-10-30	177,862,102	[10-Q 2025-11-05]
2026-02-27	180,087,915	[10-K 2026-03-05]
2026-04-30	180,087,915	[10-Q 2026-05-05]
2026-07-28	180,087,915	[10-Q 2026-08-06]

Shelf registration: S-3 filed 2025-12-30; declared effective 2026-01-07 [S-3 2025-12-30]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-10-01	Lerner Neil	buy	20,000	$0.92	[4 2026-10-02]
2026-09-24	Lerner Neil	buy	2,500	$1.14	[4 2026-09-25]
2026-04-29	Anderman Jonathan	grant	25,000	$1.89	[4 2026-04-29]
2026-04-29	Lerner Neil	grant	15,000	$1.89	[4 2026-04-29]
2026-02-08	Schuetz Thomas J.	other	36,687	$6.52	[4 2026-02-10]
2026-01-09	Schuetz Thomas J.	other	46,777	$5.35	[4 2026-01-12]
2026-01-02	Shin Barry	grant	125,000	$5.17	[4 2026-01-05]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-22	8-K	Regulation FD disclosure
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-07	13G	Beneficial ownership report (5%+ holder)
2026-08-06	10-Q	Quarterly report
2026-08-06	8-K	Results of operations
2026-07-01	8-K	Regulation FD disclosure
2026-06-23	8-K	Charter, bylaws or fiscal year change
2026-06-11	8-K	Shareholder vote results
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)
2026-05-05	10-Q	Quarterly report
2026-05-05	8-K	Results of operations
2026-04-29	DEF 14A	Proxy statement

Facts as of Oct 11, 2026, 08:07 AM UTC. Small caps move fast; check the latest filings.